Skip to content
Search

Latest Stories

NHS introduces flash glucose monitors for all type 1 diabetes patients

Type 1 diabetes patients can monitor their glucose with the newly introduced flash glucose monitors by the NHS.

The wearable gadgets with the size of a £2 coin, have a sensor that easily sits on the arm, allowing patients to check their glucose levels with a one-second scan.


Eligible patients are currently able to access the monitors on prescription from their local GP or diabetes team, helping them to better manage their blood sugar levels.

Everyone living with type 1 diabetes will be eligible for lifechanging flash glucose monitors on the NHS. The NHS Long Term Plan has already helped almost three in five people with Type 1 diabetes to access the monitors that allow people to check their glucose levels more easily and regularly.

The change, confirmed today by the National Institute for Health and Care Excellence (NICE), means that everyone in England with the condition will be able to benefit from the convenient technology.

Monitors link to an easy to use app on your phone, where people can access the data gathered by the device. Unlike conventional monitors they allow patients to view patterns over time, not only showing current and previous glucose levels but also predicting what level they can rise to.

New research presented this week at the Diabetes UK Professional Conference 2022 revealed that flash monitoring not only helps to improve blood glucose levels in people with type 1 diabetes, but also has a positive effect on their quality of life.

The NHS Long Term Plan included a target to ensure 20 per cent of people with type 1 diabetes were benefiting from flash monitors by March 2021 and recent data shows the NHS significantly exceeded that goal, with nearly three fifths already accessing the technology.

The NHS is taking radical action to tackle and treat diabetes, including through the world leading NHS Diabetes Prevention Programme with new research showing thousands of people are being spared type 2 diabetes thanks to the scheme.

The NHS in England currently spends around £10 billion a year on diabetes – around 10 per cent of its entire budget. Tools like continuous glucose monitoring, which help patients better manage their condition and reduce associated illness and hospitalisations, can prove hugely cost effective.

National NHS Specialty Adviser for Diabetes, Professor Partha Kar, said: “This announcement is the biggest step forward for type 1 diabetes care in years, allowing everyone eligible to have one of these easy to use pieces of tech if they want to – building on the success of the NHS in its rollout so far. I am delighted to see NICE endorse the use of this technology.

“These monitors are a win win – they support diabetes patients to live healthier lives, reduce their risk of hospitalisation while also helping to reduce pressure on NHS services and provide better value for money for taxpayers”.

Olivia aged 25 from Essex, who was diagnosed with type 1 diabetes aged seven said: “Before I started using a flash glucose monitor, I carried my blood glucose testing kit with me everywhere and would have to test up to eight times per day – I was pricking my finger and testing my blood sugar before breakfast, before lunch, before dinner and before bed. Before driving in the car I would need to test, and after driving for two hours I would need to stop to test – endless testing!

“Growing up with diabetes, I’d never dreamed that a device like a flash glucose monitor, where you don’t need to finger prick to know what your levels are, would be developed in my lifetime – and when I first started using one, I couldn’t quite believe something so small had such an impact on managing my diabetes.

“Since using a flash monitor, I’ve seen a huge improvement as I can make informed decisions when taking my insulin by looking at trends. But, most importantly, it’s helped me have more confidence and improved my mental well-being”.

More For You

Mike Hewitson, superintendent pharmacist & managing director of Beaminster Pharmacy

Mike Hewitson elected as NPA board member for England

Mike Hewitson elected as NPA board member for England: New term begins April

Mike Hewitson, superintendent pharmacist & managing director ofBeaminster Pharmacy, has been elected as the next National Pharmacy Association (NPA) board member for England.

Since 2023, Hewitson has served as chair of Community Pharmacy Dorset. He is also a member of Somerset Council and a Non-Executive Director at HubRx.

Keep ReadingShow less
Store closures 2024: Chemists among hardest hit

Over 600 chemist shops belonging to multiples and chains were closed last year

Getty Images

35 shops closed per day last year, chemists worst affected

More shops are expected to exit the UK high streets driven by driven by rising operational costs and a continued shift towards online shopping and transactions.

According to figures from PwC, a total of 12,804 outlets operated by chains (those with five or more locations) exited high streets, shopping centres and retail parks in 2024 – equivalent to 35 closures per day.

Keep ReadingShow less
Empty pharmacy shelves due to UK medicine shortages.

The government has said it's investing up to £520m to manufacture more medicines

Pic credit: iStock

Brexit blamed for UK medicine shortages with "little sign of recovery"

The UK is facing “a worsening situation” with drugs shortages compared to the rest of Europe as a result of Brexit, according to the Nuffield Trust health thinktank.

It comes of the back of data that revealed that the department of health and social care (DHSC) received 1,938 notifications of disruptions to medicine supply last year – the highest in four years.

Keep ReadingShow less
Alert! Patients on Promixin should be switched to alternatives by 30 April

Promixin is licensed for treating chronic pulmonary infections caused by Pseudomonas aeruginosa in adults and children with cystic fibrosis

Getty Images

Medicine shortage: Promixin to be discontinued from May 2025

The Department of Health and Social Care (DHSC) and NHS England have issued a national patient safety alert regarding the upcoming shortage of Promixin (colistimethate).

The alert, issued on 17 March 2025, states that Promixin (colistimethate) 1-million-unit powder for nebuliser solution unit dose vials (UDVs) will be discontinued from early May 2025, with stocks expected to be exhausted by this time.

Keep ReadingShow less
PAGB welcomes new vice-presidents and treasurer to Board

Rob Elliott and Bas Vorsteveld ( L-R)

Bas Vorsteveld will now oversee the Kenvue’s business in Northern Europe

PAGB appoints new vice-presidents and treasurer to Board

PAGB, the consumer healthcare association, has announced the appointment of two new vice-presidents and a treasurer to their Board.

Bas Vorsteveld, area managing director for Northern Europe at Kenvue, and Rob Elliott, OTC centre of excellence lead at Viatris, have been elected as vice-presidents.

Keep ReadingShow less